Pure Bioscience Enters Material Agreement, Reports Equity Sales
Ticker: PURE · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1006028
| Field | Detail |
|---|---|
| Company | Pure Bioscience, Inc. (PURE) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $500,000, $3 million, $0.13, $0.21 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Pure Bioscience just signed a big deal and sold some stock. Details TBD.
AI Summary
Pure Bioscience, Inc. entered into a material definitive agreement on March 22, 2024, which involves a direct financial obligation. The company also reported unregistered sales of equity securities. Specific details regarding the agreement and the financial obligation are not fully disclosed in this filing.
Why It Matters
This filing indicates new financial commitments and equity transactions for Pure Bioscience, Inc., which could impact its financial structure and shareholder equity.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement and financial obligations, suggesting potential financial risks or opportunities that are not fully detailed.
Key Players & Entities
- Pure Bioscience, Inc. (company) — Registrant
- March 22, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Pure Bioscience, Inc. on March 22, 2024?
The filing states that Pure Bioscience, Inc. entered into a material definitive agreement on March 22, 2024, but does not provide specific details about its nature.
What type of direct financial obligation did Pure Bioscience, Inc. undertake?
The filing indicates the creation of a direct financial obligation by Pure Bioscience, Inc., but the specifics of this obligation are not detailed.
Were there any unregistered sales of equity securities by Pure Bioscience, Inc. reported in this filing?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information.
What is the Central Index Key (CIK) for Pure Bioscience, Inc.?
The Central Index Key for Pure Bioscience, Inc. is 0001006028.
What is the SEC file number for Pure Bioscience, Inc.?
The SEC file number for Pure Bioscience, Inc. is 001-14468.
Filing Stats: 1,166 words · 5 min read · ~4 pages · Grade level 11.8 · Accepted 2024-03-27 17:00:49
Key Financial Figures
- $500,000 — with an aggregate principal balance of $500,000 (the "Private Placement").The Notes Doc
- $3 million — sings for an aggregate offering size of $3 million in principal balance. The Notes Docum
- $0.13 — that such conversion price is at least $0.13 per share and less than or equal to $0.
- $0.21 — .13 per share and less than or equal to $0.21 per share, subject to certain customary
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex4-1.htm (EX-4.1) — 20KB
- ex10-1.htm (EX-10.1) — 180KB
- 0001493152-24-011536.txt ( ) — 452KB
- pure-20240322.xsd (EX-101.SCH) — 3KB
- pure-20240322_lab.xml (EX-101.LAB) — 33KB
- pure-20240322_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PURE BIOSCIENCE, INC. Dated: March 27, 2024 By: /s/ Robert Bartlett Robert Bartlett President and Chief Executive Officer (Principal Executive Officer)